Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2014; 6(11): 825-829
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.825
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.825
Figure 1 Transthoracic echocardiography performed before and after treatment.
A: Transthoracic echocardiography (TTE) performed before treatment. The parasternal short axis view at the basal level in diastole shows pronounced interventricular septal deviation toward the left ventricle accompanied by pericardial effusion; B: TTE performed after treatment. The parasternal short axis view at the basal level in diastole shows a decrease in the interventricular septal deviation toward the left ventricle. Pericardial effusion has disappeared. RV: Right ventricle; LV: Left ventricle.
Figure 2 Clinical course and treatment of case 1.
Plasma brain natriuretic peptide concentration remarkably decreased from 2212 pg/mL to 46 pg/mL by intravenous dobutamin infusion and subsequent oral ambrisentan-tadalafil combination treatment.
Figure 3 Transthoracic echocardiography performed before and after treatment.
A: Pre-treament. Transthoracic echocardiography (TTE) performed before treatment. The parasternal short axis view at the basal level in diastole shows pronounced interventricular septal deviation toward the left ventricle accompanied by pericardial effusion; B: Five-month after treament. TTE performed after treatment. The parasternal short axis view at the basal level in diastole shows a decrease in the interventricular septal deviation toward the left ventricle. The pericardial effusion has disappeared. RV: Right ventricle; LV: Left ventricle.
Figure 4 Clinical course and treatment of case 2.
Plasma brain natriuretic peptide concentration remarkably decreased from 1897 pg/mL to 139 pg/mL by intravenous dobutamin infusion and oral ambrisentan-tadalafil combination treatment.
- Citation: Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol 2014; 6(11): 825-829
- URL: https://www.wjgnet.com/1948-5182/full/v6/i11/825.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i11.825